ReproSil Chiral-AGP is a silica-based HPLC stationary phase modified with immobilized α₁-acid glycoprotein (AGP), specifically designed for enantioselective separations based on protein–ligand interactions. The immobilized AGP acts as a natural chiral selector, providing multiple stereochemically active binding sites that enable highly selective recognition of chiral analytes through a combination of hydrogen bonding, hydrophobic interactions, electrostatic forces, and steric complementarity.
The protein coating is covalently bound to high-purity spherical silica, ensuring excellent mechanical stability, chemical robustness, and long column lifetime. The immobilization process preserves the tertiary structure and chiral binding capability of the AGP, allowing precise, reproducible separations of a broad variety of pharmaceuticals, metabolites, and biologically active compounds.
ReproSil Chiral-AGP can be operated under aqueous, buffered, or mixed organic/aqueous mobile phase conditions, providing flexibility in method development and compatibility with polar and moderately hydrophobic analytes. The phase is particularly suited for bioanalytical and pharmaceutical applications that require biologically relevant enantioselective separations or the study of stereoselective drug–protein interactions.
ReproSil Chiral-AGP combines the biological selectivity of α₁-acid glycoprotein with the stability of high-purity silica – the reliable choice for accurate, reproducible, and biologically relevant enantioselective separations in protein-based chiral chromatography.
Attractive Alternative to CHIRALPAK® AGP (Daicel®).
Silica-based stationary phase with covalently immobilized α₁-acid glycoprotein (AGP)
Protein-based chiral selector for biologically relevant enantioselective separations
Multiple interaction mechanisms: hydrogen bonding, hydrophobic, and electrostatic interactions
High mechanical and chemical stability with reproducible performance
Operates under aqueous and mixed mobile phase conditions
Suitable for analytical and bioanalytical HPLC applications
Enantioselective analysis of chiral pharmaceuticals, metabolites, and bioactive compounds
Investigation of protein–ligand and drug–protein interactions
Determination of stereochemical purity and pharmacokinetic profiling
Method development in pharmaceutical, biochemical, and clinical research
| Particle Size |
|
|---|---|
| Pore Size | 300 Å |
| Surface Area | 100 m²/g |
| Phase/Modification | α1-acid glycoprotein |
| Particle Type | |
| Separation Mode | |
| USP Code | |
| Endcapping | No |
| pH Range | 2 to 8 |
| Phase | Material Number |
|---|---|
| ReproSil Chiral-AGP, 5 µm | r35.agp. |